Clinical Trial Update: Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16 [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating safety and pharmacokinetics of BIVIGAM in children with primary immune deficiency has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Deficiency

Drugs mentioned

• BIVIGAM (anti-D immunoglobulin? (Note: BIVIGAM is a human intravenous immunoglobulin product))

Snippet

Sponsor: ADMA Biologics, Inc. | Conditions: Humoral Immune Response | Phase 4 | Status: COMPLETED